Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, novembre 20
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Pharming Group
PHAR
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$12.28
-0.20
-1.63%
À la clôture: Nov 19, 4:00 PM EST
$12.29
-0.19
-1.55%
Pré-ouverture: 8:55 AM EST
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Comparer
Rapport sur les stocks
Pharming Financials
Pharming (PHAR) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Pharming Affirms FY2026 Sales Guidance of $380.000M-$390.000M vs $383.333M Est
Pharming (NASDAQ:PHAR) affirms FY2026 sales outlook from $380.000 million-$390.000 million to $380.000 million-$390.000 million vs $383.333 million estimate.
Benzinga Newsdesk
PRO
Pharming Q3 EPS $0.30 Beats $0.02 Estimate, Sales $117.600M Miss $117.733M Estimate
Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.02 by 1400 percent. This is a 200 percent increase over earnings of $0.10 per share from the same
Benzinga Newsdesk
PRO
Pharming Narrows FY2026 Sales Guidance from $375.000M-$395.000M to $380.000M-$390.000M vs $389.333M Est
Pharming (NASDAQ:PHAR) narrows FY2026 sales outlook from $375.000 million-$395.000 million to $380.000 million-$390.000 million vs $389.333 million estimate.
Benzinga Newsdesk
PRO
Pharming Reports Preliminary Q3 Revenues $117.6M, Up 21% YoY; Operating Expenses $74.6M Vs $74.5M YoY; Napazimone FALCON Trial Enrollment Now Expected Complete In First Half 2027, 2026 Revenue Guidance Tightened To $380M-$390M From $375M-$395M
Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025Third quarter 2026 total operating expenses of approximately US$74.6 million, in line with third quarter
Benzinga Newsdesk
PRO
Pharming Lowers FY2026 Sales Guidance from $405.000M-$425.000M to $375.000M-$395.000M vs $419.100M Est
Pharming (NASDAQ:PHAR) lowers FY2026 sales outlook from $405.000 million-$425.000 million to $375.000 million-$395.000 million vs $419.100 million estimate.
Benzinga Newsdesk
PRO
Pharming Q2 EPS $0.02, Inline, Sales $90.200M Miss $100.625M Estimate
Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.02 per share which met the analyst consensus estimate. This is a 66.67 percent decrease over earnings of $0.06 per share from the same period last year. The
Benzinga Newsdesk